Development of highly antibiotic resistant strains of infections such as staphylococcus and tuberculosis warrant the search for new antibacterial chemotherapies. With vanishing antibiotic therapies available for such infections and with little pharmaceutical company input into these developing world problems, it is critical for many researchers to investigate novel therapies against these bacterial threats. We are particularly interested in 1,3-Di-polar cycloaddition chemistry as an approach to heterocycles that may be pharmaceutically useful against such threats.